WX [WuXi PharmaTech (Cayman)] CT ORDER:
[]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: (Original Filing)
[TABLE OF CONTENTS Page PART I 3 Item 1. Business 3 Item 1A. Risk Factors 10 Item 1B. Unresolved Staff Comments 20 Item 2. Properties 20 Item 3. Legal Proceedings 22 Item 4. Mine Safety Disclosures 23 PART II 23 Item 5. 23 Item 7. Management’s Discussion and Analysis of Financial Conditions and Results of Operations] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-192657) and Registration Statement on Form S-8 (No. 333-181010) of our report dated March 31, 2014, relating to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and its subsidiaries (collectively the “Company”), which appears in this Annual] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Bing Mei Chief Financial Officer]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: TABLE OF CONTENTS Page PART I 3 Item
[TABLE OF CONTENTS Page PART I 3 Item 1. Business 3 Item 1A. Risk Factors 10 Item 1B. Unresolved Staff Comments 20 Item 2. Properties 20 Item 3. Legal Proceedings 22 Item 4. Mine Safety Disclosures 23 PART II 23 Item 5. 23 Item 7. Management’s Discussion and Analysis of Financial Conditions and Results of Operations] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-192657) and Registration Statement on Form S-8 (No. 333-181010) of our report dated March 31, 2014, relating to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and its subsidiaries (collectively the “Company”), which appears in this Annual] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Bing Mei Chief Financial Officer]
BSPM [Biostar Pharmaceuticals] 10-K: (Original Filing)
[FORM 10-K (Mark One) x December 31, 2013 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-192963) of Biostar Pharmaceuticals, Inc. of our report dated March 31, 2014 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K of Biostar] [CERTIFICATION I, Ronghua Wang, certify that: 1. R e I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to] [CERTIFICATION I, Qinghua Liu, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: March 31, 2014 Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: March 31, 2014 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 6 ex32-2.htm EX-32.2]
BSPM [Biostar Pharmaceuticals] 10-K: FORM 10-K (Mark One) x December 31, 2013
[FORM 10-K (Mark One) x December 31, 2013 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-192963) of Biostar Pharmaceuticals, Inc. of our report dated March 31, 2014 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K of Biostar] [CERTIFICATION I, Ronghua Wang, certify that: 1. R e I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to] [CERTIFICATION I, Qinghua Liu, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: March 31, 2014 Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: March 31, 2014 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 6 ex32-2.htm EX-32.2]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13D: (Original Filing)
[SCHEDULE 13D (Rule 13d-101) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) James M. Gregory SJ Strategic Investments, LLC 340 Martin Luther King, Jr. Boulevard, Suite 200 Bristol, TN 37620 (423) 989-8133 (Name, Address and Telephone Numbers of Person Authorized to Receive Notices and Communications) March 20, 2014 (Date of Event which]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13D: SCHEDULE 13D (Rule 13d-101) Skystar Bio-Pharmaceutical Company (Name
[SCHEDULE 13D (Rule 13d-101) Skystar Bio-Pharmaceutical Company (Name of Issuer) Common Stock (Title of Class Of Securities) 830884102 (CUSIP Number) James M. Gregory SJ Strategic Investments, LLC 340 Martin Luther King, Jr. Boulevard, Suite 200 Bristol, TN 37620 (423) 989-8133 (Name, Address and Telephone Numbers of Person Authorized to Receive Notices and Communications) March 20, 2014 (Date of Event which]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine — -Preclinical development completed for H7N9 vaccine candidates that addresses significant BEIJING, January 29, 2014—Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration(CFDA) to commence human clinical trials for] [Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New — Study shows vaccine provides protection against EV71-associated hand, foot and mouth th The New England Journal of Medicine BEIJING, Feb. 26, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 BEIJING, March 12, 2014 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014] [Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results - Conference call scheduled for Thursday, March 20, 2014 at 8:00 AM EDT - BEIJING, March 19, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December] []
SVA [SINOVAC BIOTECH] 6-K: Sinovac Files Clinical Trial Application with CFDA for
[Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine — -Preclinical development completed for H7N9 vaccine candidates that addresses significant BEIJING, January 29, 2014—Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration(CFDA) to commence human clinical trials for] [Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New — Study shows vaccine provides protection against EV71-associated hand, foot and mouth th The New England Journal of Medicine BEIJING, Feb. 26, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 BEIJING, March 12, 2014 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014] [Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results - Conference call scheduled for Thursday, March 20, 2014 at 8:00 AM EDT - BEIJING, March 19, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December] []
